MedTrace Logo

Safety and Efficacy Study in Hepatitis C Patients With PHN121

NCT01052090 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-11-26

No results posted yet for this study

Summary

To evaluate the safety, tolerability and efficacy of escalating dose of PHN121 when administered orally in non-responder hepatitis C genotype 1 patients

Conditions

  • Hepatitis C Virus Infection

Interventions

DRUG

PHN121

a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines

Sponsors & Collaborators

  • PhytoHealth Corporation

    lead INDUSTRY

Principal Investigators

  • Wan-Long Chuang, M.D., Ph.D. · Kaohsiung Municipal United Hospital

  • Ming-Lung Yu, M.D., Ph.D. · Kaohsiung Municipal United Hospital

  • Chia-Yen Dai, M.D., M.S. · Kaohsiung Municipal United Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052090 on ClinicalTrials.gov